Astrazeneca plc (AZN) RNS Announcements

Date	Time	Date	TitleTitle (filtered)	Source
23/03/20	16:36:18	23 Mar 2020	Price Monitoring Extension	Price Monitoring Extension	RNS
23/03/20	12:08:38	23 Mar 2020	Second Price Monitoring Extn	Second Price Monitoring Extn	RNS
23/03/20	12:03:00	23 Mar 2020	Price Monitoring Extension	Price Monitoring Extension	RNS
20/03/20	10:20:56	20 Mar 2020	Second Price Monitoring Extn	Second Price Monitoring Extn	RNS
20/03/20	10:15:31	20 Mar 2020	Price Monitoring Extension	Price Monitoring Extension	RNS
20/03/20	07:00:06	20 Mar 2020	Director/PDMR Shareholding	Director/PDMR Shareholding	RNS
19/03/20	07:00:07	19 Mar 2020	Lynparza granted orphan drug designation in Japan	Lynparza granted orphan drug designation in Japan	RNS
17/03/20	07:00:07	17 Mar 2020	Imfinzi confirmed overall survival in CASPIAN	Imfinzi confirmed overall survival in CASPIAN	RNS
13/03/20	16:35:55	13 Mar 2020	Price Monitoring Extension	Price Monitoring Extension	RNS
12/03/20	11:00:01	12 Mar 2020	Notice of AGM	Notice of AGM	RNS
12/03/20	07:00:04	12 Mar 2020	Update on Phase III GY004 trial for cediranib	Update on Phase III GY004 trial for cediranib	RNS
10/03/20	07:00:07	10 Mar 2020	Director/PDMR Shareholding	Director/PDMR Shareholding	RNS
06/03/20	07:00:05	6 Mar 2020	Update on Phase III DANUBE trial in bladder cancer	Update on Phase III DANUBE trial in bladder cancer	RNS
04/03/20	07:00:02	4 Mar 2020	Filing of Form 20-F with SEC	Filing of Form 20-F with SEC	RNS
03/03/20	11:00:01	3 Mar 2020	Annual Financial Report	Annual Financial Report	RNS
02/03/20	15:00:02	2 Mar 2020	Total Voting Rights	Total Voting Rights	RNS
02/03/20	07:00:06	2 Mar 2020	Divestment of hypertension medicines completed	Divestment of hypertension medicines completed	RNS
27/02/20	07:00:12	27 Feb 2020	Director/PDMR Shareholding	Director/PDMR Shareholding	RNS
25/02/20	07:00:07	25 Feb 2020	AstraZeneca divests global rights to Movantik	AstraZeneca divests global rights to Movantik	RNS
19/02/20	07:00:12	19 Feb 2020	Director/PDMR Shareholding	Director/PDMR Shareholding	RNS
14/02/20	07:00:05	14 Feb 2020	AZN: Full-year and Q4 2019 results	AZN: Full-year and Q4 2019 results	RNS
03/02/20	15:00:02	3 Feb 2020	Total Voting Rights	Total Voting Rights	RNS
03/02/20	07:00:08	3 Feb 2020	ZEGONA SHARE BUYBACK PROGRAMME – PROGRESS UPDATE	ZEGONA SHARE BUYBACK PROGRAMME – PROGRESS UPDATE	RNS
27/01/20	07:00:18	27 Jan 2020	Enhertu Phase II trial met primary endpoint	Enhertu Phase II trial met primary endpoint	RNS
27/01/20	07:00:14	27 Jan 2020	Brilinta met primary endpoint in stroke trial	Brilinta met primary endpoint in stroke trial	RNS
27/01/20	07:00:10	27 Jan 2020	AstraZeneca divests hypertension medicines	AstraZeneca divests hypertension medicines	RNS
27/01/20	07:00:09	27 Jan 2020	AstraZeneca to recover brazikumab (MEDI2070)	AstraZeneca to recover brazikumab (MEDI2070)	RNS
20/01/20	07:00:07	20 Jan 2020	Imfinzi, tremelimumab granted ODD in liver cancer	Imfinzi, tremelimumab granted ODD in liver cancer	RNS
20/01/20	07:00:07	20 Jan 2020	FDA grants Lynparza Priority Review for PROfound	FDA grants Lynparza Priority Review for PROfound	RNS
13/01/20	07:01:02	13 Jan 2020	Lynparza granted FDA Priority Review for PAOLA-1	Lynparza granted FDA Priority Review for PAOLA-1	RNS
13/01/20	07:00:06	13 Jan 2020	Update on Epanova Phase III STRENGTH trial	Update on Epanova Phase III STRENGTH trial	RNS
06/01/20	07:01:04	6 Jan 2020	Farxiga granted FDA heart failure Priority Review	Farxiga granted FDA heart failure Priority Review	RNS
06/01/20	07:00:07	6 Jan 2020	Lokelma approved in China for hyperkalaemia	Lokelma approved in China for hyperkalaemia	RNS
02/01/20	15:00:04	2 Jan 2020	Total Voting Rights	Total Voting Rights	RNS
30/12/19	07:00:07	30 Dec 2019	US FDA approved Lynparza for pancreatic cancer	US FDA approved Lynparza for pancreatic cancer	RNS
23/12/19	07:00:11	23 Dec 2019	Triple-combination approved in China for COPD	Triple-combination approved in China for COPD	RNS
23/12/19	07:00:09	23 Dec 2019	Enhertu (trastuzumab deruxtecan) approved in US	Enhertu (trastuzumab deruxtecan) approved in US	RNS
20/12/19	07:00:07	20 Dec 2019	AstraZeneca divests rights to Arimidex and Casodex	AstraZeneca divests rights to Arimidex and Casodex	RNS
17/12/19	18:06:33	17 Dec 2019	FDA panel backs Lynparza use for pancreatic cancer	FDA panel backs Lynparza use for pancreatic cancer	RNS
16/12/19	07:00:10	16 Dec 2019	Seroquel rights agreement complete: Europe, Russia	Seroquel rights agreement complete: Europe, Russia	RNS
12/12/19	07:00:17	12 Dec 2019	Imfinzi approved in China for Stage III NSCLC	Imfinzi approved in China for Stage III NSCLC	RNS
11/12/19	13:00:01	11 Dec 2019	Trastuzumab deruxtecan achieves ORR of 60.9%	Trastuzumab deruxtecan achieves ORR of 60.9%	RNS
05/12/19	07:00:13	5 Dec 2019	Lynparza approved in China for 1L BRCAm ovarian	Lynparza approved in China for 1L BRCAm ovarian	RNS
03/12/19	07:00:10	3 Dec 2019	AstraZeneca divests Seroquel rights: US and Canada	AstraZeneca divests Seroquel rights: US and Canada	RNS
02/12/19	15:00:04	2 Dec 2019	Block listing Interim Review	Block listing Interim Review	RNS
02/12/19	15:00:04	2 Dec 2019	Total Voting Rights	Total Voting Rights	RNS
29/11/19	07:00:04	29 Nov 2019	Imfinzi granted FDA Priority Review for SCLC	Imfinzi granted FDA Priority Review for SCLC	RNS
21/11/19	18:15:04	21 Nov 2019	Calquence approved in CLL in the US	Calquence approved in CLL in the US	RNS
15/11/19	07:00:03	15 Nov 2019	Qtrilmet approved in the EU for treatment of T2D	Qtrilmet approved in the EU for treatment of T2D	RNS
14/11/19	07:00:08	14 Nov 2019	FDA accepts regulatory submission for selumetinib	FDA accepts regulatory submission for selumetinib	RNS

Showing 701–750 of 1,436 announcements

Astrazeneca plc RNS

Astrazeneca plc RNS